Vallon Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary

GRI Bio

12/05/2022 13:05

* Vallon Pharmaceuticals Inc  VLON.OQ  reported a quarterly
adjusted loss of 39 cents​​ per share for the quarter ended in
March. The lone analyst forecast for the quarter was for a loss
of 22 cents per share.
    * Reported revenue was zero​;  analysts expected zero. 
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Vallon Pharmaceuticals Inc shares had fallen by 45.7% this
quarter and lost 82.9% so far this year.
    * Wall Street's median 12-month price target for Vallon
Pharmaceuticals Inc is $12.00 

This summary was machine generated May 12 at 12:05 p.m.  ​All
figures in US dollars unless otherwise stated